Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.

書目詳細資料
Main Authors: Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Wolfgang, H
格式: Conference item
出版: 2012

相似書籍